1. Known severe allergic reactions to monoclonal antibodies <br/ >2. Active tuberculosis (TB) infection <br/ >3. History of inadequately treated tuberculosis or latent tuberculosis <br/ >4. In the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments <br/ >5. Have received oral anti-rejection or immune-suppressive drugs within the past 6 months <br/ >6. Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor) <br/ >7. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination <br/ >8. Patients with known history of Hepatitis B, Hepatitis C or HIV <br/ >9. Absolute Neutrophils count (ANC) <1000 / mm3 <br/ >10. Platelets <50,000 / mm3 <br/ >11. Absolute Lymphocyte count (ALC): <500/mm3 <br/ > <br/ >

1. Known severe allergic reactions to monoclonal antibodies <br/ >2. Active tuberculosis (TB) infection <br/ >3. History of inadequately treated tuberculosis or latent tuberculosis <br/ >4. In the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments <br/ >5. Have received oral anti-rejection or immune-suppressive drugs within the past 6 months <br/ >6. Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor) <br/ >7. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination <br/ >8. Patients with known history of Hepatitis B, Hepatitis C or HIV <br/ >9. Absolute Neutrophils count (ANC) <1000 / mm3 <br/ >10. Platelets <50,000 / mm3 <br/ >11. Absolute Lymphocyte count (ALC): <500/mm3 <br/ > <br/ >

N/A

N/A

1. Known severe allergic reactions to monoclonal antibodies <br/ >2. Active tuberculosis (TB) infection <br/ >3. History of inadequately treated tuberculosis or latent tuberculosis <br/ >4. In the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments <br/ >5. Have received oral anti-rejection or immune-suppressive drugs within the past 6 months <br/ >6. Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor) <br/ >7. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination <br/ >8. Patients with known history of Hepatitis B, Hepatitis C or HIV <br/ >9. Absolute Neutrophils count (ANC) <1000 / mm3 <br/ >10. Platelets <50,000 / mm3 <br/ >11. Absolute Lymphocyte count (ALC): <500/mm3 <br/ > <br/ >

1. Known severe allergic reactions to monoclonal antibodies <br/ >2. Active tuberculosis (TB) infection <br/ >3. History of inadequately treated tuberculosis or latent tuberculosis <br/ >4. In the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments <br/ >5. Have received oral anti-rejection or immune-suppressive drugs within the past 6 months <br/ >6. Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor) <br/ >7. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination <br/ >8. Patients with known history of Hepatitis B, Hepatitis C or HIV <br/ >9. Absolute Neutrophils count (ANC) <1000 / mm3 <br/ >10. Platelets <50,000 / mm3 <br/ >11. Absolute Lymphocyte count (ALC): <500/mm3 <br/ > <br/ >